var data={"title":"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/contributors\" class=\"contributor contributor_credentials\">Brian S Decker, MD, PharmD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/contributors\" class=\"contributor contributor_credentials\">Bruce A Molitoris, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/contributors\" class=\"contributor contributor_credentials\">Paul M Palevsky, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/contributors\" class=\"contributor contributor_credentials\">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/contributors\" class=\"contributor contributor_credentials\">Alice M Sheridan, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 26, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main concerns with the use of aminoglycoside antibiotics are nephrotoxicity and ototoxicity. This topic will review what is known about the pathogenesis of these complications and how the nephrotoxicity might be prevented. The manifestations of and risk factors for aminoglycoside nephrotoxicity are discussed separately. (See <a href=\"topic.htm?path=manifestations-of-and-risk-factors-for-aminoglycoside-nephrotoxicity\" class=\"medical medical_review\">&quot;Manifestations of and risk factors for aminoglycoside nephrotoxicity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">NEPHROTOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute kidney injury (AKI) due to acute tubular necrosis is a relatively common complication of aminoglycoside therapy, with a rise in the serum creatinine concentration of more than 0.5 to 1 <span class=\"nowrap\">mg/dL</span> (44 to 88 <span class=\"nowrap\">micromol/L)</span> or a 50 percent increase in serum creatinine concentration from baseline occurring in 10 to 20 percent of patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Aminoglycosides are freely filtered across the glomerulus; almost all of the drug is then excreted, with 5 to 10 percent of a parenteral dose being taken up and sequestered by the proximal tubule cells (PTCs), where the aminoglycoside can achieve concentrations vastly exceeding the concurrent serum concentration [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The intracellular accumulation of aminoglycosides is confined primarily to the S1 and S2 segments of the proximal tubule. However, following renal ischemia, the S3 portion is also a site of intracellular aminoglycoside concentrations. AKI can occur even if drug levels are closely monitored [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Dose frequency also may be important as multiple human studies suggest that giving a large dose of aminoglycoside once a day is as effective an antimicrobial regimen and less nephrotoxic than giving aminoglycosides in the conventional, divided-dose regimen [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/5-9\" class=\"abstract_t\">5-9</a>] (see <a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides\" class=\"medical medical_review\">&quot;Dosing and administration of parenteral aminoglycosides&quot;</a>). Aminoglycosides may also have a deleterious effect on the developing kidney in preterm and small for gestational age infants [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Renal transport of aminoglycosides</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Proximal tubule cell transport and charge</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple amine groups on the aminoglycoside molecule confer a cationic charge at physiologic pH [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/11,12\" class=\"abstract_t\">11,12</a>]. As a result, aminoglycoside molecules readily bind to anion phospholipids within the plasma membrane of the PTC in a saturable, electrostatic manner [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/11-14\" class=\"abstract_t\">11-14</a>]. The relative affinity of an aminoglycoside for the PTC plasma membrane correlates with the nephrotoxicity observed in clinical practice [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/4,15-17\" class=\"abstract_t\">4,15-17</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=neomycin-drug-information\" class=\"drug drug_general\">Neomycin</a>, which has the highest affinity for the PTC binding site, has the greatest nephrotoxicity of the aminoglycosides.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tobramycin-drug-information\" class=\"drug drug_general\">Tobramycin</a> and <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> have lower binding affinity, conferring less nephrotoxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">Amikacin</a> has even less binding affinity and, likewise, has less nephrotoxic potential than <a href=\"topic.htm?path=tobramycin-drug-information\" class=\"drug drug_general\">tobramycin</a> and <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">Streptomycin</a>, which has the least affinity for the PTC binding site, has the least nephrotoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/4,15,16\" class=\"abstract_t\">4,15,16</a>].</p><p/><p>After the aminoglycoside binds to the anionic phospholipid of the PTC, it is rapidly transferred to the transmembrane protein megalin and endocytosed [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/11,12,18-33\" class=\"abstract_t\">11,12,18-33</a>]. Megalin is a 600 kD cell surface receptor and has a high affinity for proteins, with regions of positively charged amino acids. It is abundantly expressed in the renal proximal tubules and many other tissues, including glomerular podocytes and ciliary and inner ear epithelium [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/11,24,34\" class=\"abstract_t\">11,24,34</a>].</p><p>Once megalin-mediated endocytosis has occurred, endosomes containing the aminoglycosides are transported through the endocytic system, where they co-localize to lysosomes and, in a retrograde fashion, to the Golgi complex [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/31,35-38\" class=\"abstract_t\">31,35-38</a>]. From the Golgi complex, aminoglycosides traffic in a retrograde fashion to the endoplasmic reticulum and then to the cytosol [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/39-42\" class=\"abstract_t\">39-42</a>]. In the cytosol, aminoglycoside molecules accumulate in subcellular organelles such as the mitochondria and the nucleus [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/41\" class=\"abstract_t\">41</a>].</p><p>This pathway of the aminoglycosides to the Golgi complex and subcellular organelles is consistent with the disruption in both protein sorting and synthesis and mitochondrial function observed in aminoglycoside nephrotoxicity.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Prevention</span></p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Clinical strategies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical strategies that may minimize the potential for nephrotoxicity include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Selection of the least toxic aminoglycoside, when possible. <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">Gentamicin</a> is considered the most nephrotoxic, followed in decreasing order of nephrotoxicity by <a href=\"topic.htm?path=tobramycin-drug-information\" class=\"drug drug_general\">tobramycin</a>, <a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a>, netilmicin, and <a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">streptomycin</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Correcting hypokalemia and hypomagnesemia prior to administering an aminoglycoside.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other effective clinical strategies include avoiding aminoglycosides in patients with reduced effective arterial volume (or optimizing volume status prior to giving aminoglycosides), adjusting the dose for renal function, limiting the duration of therapy to 7 to 10 days, and minimizing concomitant nephrotoxic medications [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pharmacokinetically monitoring aminoglycoside therapy and utilizing a once-daily dosing regimen in selected patients have also demonstrated benefit [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/5-7,43-46\" class=\"abstract_t\">5-7,43-46</a>]. (See <a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides\" class=\"medical medical_review\">&quot;Dosing and administration of parenteral aminoglycosides&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several agents have emerged as potential compounds to prevent aminoglycoside nephrotoxicity. Despite their potential, none have been adopted clinically for the prevention of aminoglycoside nephrotoxicity.</p><p>One class of compounds, the anionic polyamino acids (PAAs), which include polyaspartic acid and polyglutamic acid, has been extensively evaluated [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/12,42,47-53\" class=\"abstract_t\">12,42,47-53</a>]. Early studies showed that PAA interferes with the binding of the aminoglycoside to the PTC plasma membrane [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/51-53\" class=\"abstract_t\">51-53</a>]. Subsequent work showed that PAA binds directly to aminoglycosides and can displace them from negatively charged lysosomes [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/54\" class=\"abstract_t\">54</a>]. This led researchers to postulate that PAA affords renal protection by directly binding to the aminoglycoside or by displacing it from the lysosome and thus preventing its trafficking through the PTC [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/54\" class=\"abstract_t\">54</a>].</p><p>Other compounds evaluated for their potential role in preventing aminoglycoside nephrotoxicity include antioxidants. As examples, desferrioxamine, <a href=\"topic.htm?path=methimazole-drug-information\" class=\"drug drug_general\">methimazole</a>, vitamin E, <a href=\"topic.htm?path=vitamin-c-ascorbic-acid-drug-information\" class=\"drug drug_general\">vitamin C</a>, and <a href=\"topic.htm?path=selenium-drug-information\" class=\"drug drug_general\">selenium</a> have been effective in preventing <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> nephrotoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/42,55,56\" class=\"abstract_t\">42,55,56</a>]. Superoxide dismutase, lipoic acid, dimethyl-sulfoxide (DMSO), N-acetylcysteine (NAC), and melatonin have also demonstrated utility in preventing aminoglycoside nephrotoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/55,57-62\" class=\"abstract_t\">55,57-62</a>].</p><p>A <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> congener that retains its antimicrobial efficacy and yet lacks the potential for aminoglycoside nephrotoxicity has been isolated. Commercially available gentamicin is not a homogeneous compound; rather, it is a mixture of C1, C1a, C2, and C2a congeners that differ in their nephrotoxic potential [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/63\" class=\"abstract_t\">63</a>]. The C2 compound was the specific congener shown to be bactericidal but not nephrotoxic [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/63\" class=\"abstract_t\">63</a>]. Via immunofluorescent techniques, the C2 congener is transported intracellularly to the Golgi complex in reduced quantities. This is likely the reason for its lack of nephrotoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/63\" class=\"abstract_t\">63</a>].</p><p>Independent of their antimicrobial activity, aminoglycosides are characterized by their ability to induce read-through of premature termination codons, making them potential therapies in the treatment of inherited diseases such as cystic fibrosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/64-69\" class=\"abstract_t\">64-69</a>]. Research to develop designer aminoglycosides for this purpose has led to the discovery of aminoglycoside derivatives with less cellular toxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/64-67\" class=\"abstract_t\">64-67</a>]. However, such compounds also have decreased bactericidal activity and thus would not be effective antibiotics [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/64,67\" class=\"abstract_t\">64,67</a>]. Ongoing research in this area may lead to the discovery of other aminoglycoside derivatives that maintain antibacterial efficacy while minimizing cellular toxicity.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">OTOTOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Aminoglycosides are associated with cochlear and vestibular toxicity in a substantial proportion of patients receiving the drug for prolonged periods, leading to hearing loss and disequilibrium, respectively [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/70\" class=\"abstract_t\">70</a>]. The relative frequency with which these occur is uncertain, and both may not be clinically evident in the same patient. In one series of 33 patients presenting to a neurology clinic with vestibular symptoms, formal audiology testing revealed that 10 of 27 tested patients did not have associated hearing loss greater than expected for age [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/71\" class=\"abstract_t\">71</a>]. In a later report on 25 patients, most were found to have no residual hearing loss [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/70\" class=\"abstract_t\">70</a>].</p><p>The clinical findings and diagnosis of individuals with aminoglycoside vestibulotoxicity are presented separately. (See <a href=\"topic.htm?path=pathophysiology-etiology-and-differential-diagnosis-of-vertigo#H16\" class=\"medical medical_review\">&quot;Pathophysiology, etiology, and differential diagnosis of vertigo&quot;, section on 'Aminoglycoside toxicity'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of aminoglycoside-induced ototoxicity with hearing loss is less understood. Sustained or excessive peak serum concentrations are thought to be a risk factor.</p><p>One hypothesis is related to receptors for N-methyl-D-aspartate (NMDA), which are present at the synapse between cochlear hair cells and neural afferents [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/72\" class=\"abstract_t\">72</a>]. Aminoglycosides can mimic the positive modulation of polyamines at these receptors, possibly producing excitotoxic damage. The observation that the administration of NMDA antagonists markedly attenuates hearing loss in animals is consistent with this hypothesis. Furthermore, there is a high correlation between in vitro activation of the receptor and relative cochlear toxicity in humans (<a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> &gt; <a href=\"topic.htm?path=tobramycin-drug-information\" class=\"drug drug_general\">tobramycin</a> &gt; <a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a> &gt; <a href=\"topic.htm?path=neomycin-drug-information\" class=\"drug drug_general\">neomycin</a>). In addition to these functional changes, aminoglycosides also may induce structural changes, such as loss of target innervation and degeneration of spiral ganglion neurons [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/73\" class=\"abstract_t\">73</a>].</p><p>Another possibility is that aminoglycosides create reactive oxygen species that damage the inner ear. Support for this hypothesis includes the findings of aminoglycoside-induced reactive oxygen species in vitro and experimental evidence in animals showing ototoxicity prevention with antioxidant agents [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/74,75\" class=\"abstract_t\">74,75</a>].</p><p>There appears to be a genetic predisposition to the development of ototoxicity with aminoglycosides. Point mutations in the small (12S) ribosomal RNA gene have been described in a number of families with inherited susceptibility to ototoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/76,77\" class=\"abstract_t\">76,77</a>]. The mutant human RNA binds aminoglycosides with high affinity; in comparison, the wild-type human RNA does not bind aminoglycosides at all [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/78\" class=\"abstract_t\">78</a>]. The presumed mechanism is that aminoglycoside binding exacerbates the inherent defect induced by the mutation, resulting in a reduction in the overall translation rate below the minimum level required for normal cellular function [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/79\" class=\"abstract_t\">79</a>]. The prevalence of such point mutations among individuals of European ancestry is approximately 1 in 500 [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/80,81\" class=\"abstract_t\">80,81</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Prevention of ototoxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Traditionally, a number of the strategies used to help prevent the development of ototoxicity due to aminoglycosides are the same as those used to prevent nephrotoxicity. These strategies include once-daily dosing and careful monitoring of serum drug concentrations. However, ototoxicity has been reported even in those with target serum levels and once-daily dosing [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/5,71\" class=\"abstract_t\">5,71</a>]. (See <a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides#H7\" class=\"medical medical_review\">&quot;Dosing and administration of parenteral aminoglycosides&quot;, section on 'Ototoxicity'</a>.)</p><p>Another approach is to use audiometric testing among patients receiving aminoglycoside therapy. However, hearing loss may occur even after the termination of antibiotic therapy [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/71,82\" class=\"abstract_t\">71,82</a>].</p><p>Genetic screening of patients prior to administering of aminoglycosides would be a valuable tool to aid in the prevention of ototoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/80,81\" class=\"abstract_t\">80,81</a>]. However, there are no rapid screening tests commercially available that provide results in a clinically relevant timeframe. The patient and family history remain our most valuable tools available to prevent aminoglycoside-induced ototoxicity.</p><p>In addition, given the relative rarity of the 12S ribosomal point-mutations that confer susceptibility to aminoglycoside-induced hearing loss, it is unlikely that it would be economically feasible to perform general screening or for most laboratories to carry these diagnostic tests. Although aminoglycosides remain powerful tools in our antibiotic armamentarium, there are reasonable alternatives that provide similar spectrums of bacterial coverage. For patients that require gram-negative bacterial coverage and whose personal or family history suggests a risk for ototoxicity, considering these antibiotic alternatives may be a more prudent approach.</p><p>Based upon the observations that oxidative stress may cause ototoxicity, the efficacy of N-acetylcysteine (NAC), a thiol-containing antioxidant, was evaluated in hemodialysis patients receiving <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/83\" class=\"abstract_t\">83</a>]. In this study, 53 hemodialysis patients with catheter-induced bacteremia were randomly assigned to gentamicin plus NAC (600 mg twice daily) or gentamicin alone. Pure-tone audiograms were performed at baseline, one week, and at six weeks after gentamicin therapy was stopped. NAC was given until the first otologic examination, which was approximately one week after completion of antibiotic therapy. Compared with the control group, NAC therapy significantly lowered the incidence of audiologic toxicity (25 versus 60 percent). Protection primarily occurred in the high-frequency range, and NAC was not associated with any adverse effects.</p><p>Another study that included 60 patients on continuous ambulatory peritoneal dialysis (CAPD) suggested that oral administration of NAC prevented ototoxicity related to intraperitoneal <a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a> and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> and may have improved high-frequency function at four weeks [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/84\" class=\"abstract_t\">84</a>].</p><p>Further study in a larger number of patients and other clinical settings is required to better understand the role of NAC in preventing ototoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/85\" class=\"abstract_t\">85</a>]. However, given the proven safety of NAC and the severity and irreversibility of aminoglycoside-induced ototoxicity, a reasonable argument can be made that NAC should be administered to all end-stage renal disease (ESRD) patients receiving an aminoglycoside. Such therapy can be particularly considered in hemodialysis patients with existing hearing loss due to previous exposure to aminoglycosides.</p><p>Limited evidence in nondialysis patients suggests that <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> may provide some protection against ototoxicity [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/86-88\" class=\"abstract_t\">86-88</a>]. Whether this finding extends to dialysis patients without causing significant adverse effects is unclear.</p><p>Less ototoxic forms of aminoglycosides may also be useful in preventing ototoxicity. An animal study of an aminoglycoside congener (N1MS) has demonstrated excellent activity against <em>Escherichia coli, Klebsiella pneumoniae, </em>and extended-spectrum B-lactamases while preserving hair cells and hearing relative to its parent compound [<a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/89\" class=\"abstract_t\">89</a>].</p><p class=\"headingAnchor\" id=\"H481347434\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-chronic-kidney-disease-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Chronic kidney disease in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute kidney injury (AKI) due to acute tubular necrosis is a relatively common complication of aminoglycoside therapy, affecting 10 to 20 percent of patients. (See <a href=\"#H2\" class=\"local\">'Nephrotoxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Since aminoglycoside molecules readily bind to anionic phospholipids within the plasma membrane of the proximal tubule cell (PTC) in a saturable, electrostatic manner, the relative affinity of an aminoglycoside for the PTC plasma membrane correlates with the nephrotoxicity observed in clinical practice. (See <a href=\"#H4\" class=\"local\">'Proximal tubule cell transport and charge'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For prevention, clinical strategies are primarily utilized to minimize the potential for nephrotoxicity. These include selection of the least toxic aminoglycoside when possible, correcting hypokalemia and hypomagnesemia prior to administering an aminoglycoside, avoiding aminoglycosides in patients with reduced effective arterial volume, adjusting the dose for renal function, limiting the duration of therapy to 7 to 10 days, and minimizing concomitant nephrotoxic medications. We suggest utilizing a once-daily dosing regimen in selected patients. (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H6\" class=\"local\">'Clinical strategies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although several agents have emerged as potential compounds to prevent aminoglycoside nephrotoxicity, none have been adopted clinically for the prevention of aminoglycoside nephrotoxicity. (See <a href=\"#H7\" class=\"local\">'Agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aminoglycosides are associated with cochlear and vestibular toxicity in a substantial proportion of patients receiving the drug for prolonged periods, leading to hearing loss and disequilibrium, respectively. The pathogenesis of aminoglycoside-induced ototoxicity with hearing loss is less understood. (See <a href=\"#H8\" class=\"local\">'Ototoxicity'</a> above and <a href=\"#H9\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To prevent the development of ototoxicity due to aminoglycosides, strategies include once-daily dosing and careful monitoring of serum drug concentrations. N-acetylcysteine (NAC) can also be considered among patients with end-stage renal disease (ESRD) receiving an aminoglycoside. (See <a href=\"#H10\" class=\"local\">'Prevention of ototoxicity'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/1\" class=\"nounderline abstract_t\">Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/2\" class=\"nounderline abstract_t\">Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/3\" class=\"nounderline abstract_t\">Gall&oslash;e AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48:39.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/4\" class=\"nounderline abstract_t\">Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302:1106.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/5\" class=\"nounderline abstract_t\">Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/6\" class=\"nounderline abstract_t\">Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124:717.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/7\" class=\"nounderline abstract_t\">Ferriols-Lisart R, Al&oacute;s-Almi&ntilde;ana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/8\" class=\"nounderline abstract_t\">Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312:338.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/9\" class=\"nounderline abstract_t\">Prins JM, B&uuml;ller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341:335.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/10\" class=\"nounderline abstract_t\">Samiee-Zafarghandy S, van den Anker JN. Nephrotoxic effects of the aminoglycosides on the developing kidney. J Ped Neonat Individ Med 2013; 2:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/11\" class=\"nounderline abstract_t\">Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004; 19:159.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/12\" class=\"nounderline abstract_t\">Sastrasinh M, Knauss TC, Weinberg JM, Humes HD. Identification of the aminoglycoside binding site in rat renal brush border membranes. J Pharmacol Exp Ther 1982; 222:350.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/13\" class=\"nounderline abstract_t\">Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236:470.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/14\" class=\"nounderline abstract_t\">Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43:1003.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/15\" class=\"nounderline abstract_t\">Smith CR, Baughman KL, Edwards CQ, et al. Controlled comparison of amikacin and gentamicin. N Engl J Med 1977; 296:349.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/16\" class=\"nounderline abstract_t\">Lerner AM, Reyes MP, Cone LA, et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983; 1:1123.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/17\" class=\"nounderline abstract_t\">Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987; 31:570.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/18\" class=\"nounderline abstract_t\">Moestrup SK, Cui S, Vorum H, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96:1404.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/19\" class=\"nounderline abstract_t\">Hammond TG, Majewski RR, Kaysen JH, et al. Gentamicin inhibits rat renal cortical homotypic endosomal fusion: role of megalin. Am J Physiol 1997; 272:F117.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/20\" class=\"nounderline abstract_t\">Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002; 3:256.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/21\" class=\"nounderline abstract_t\">Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280:F562.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/22\" class=\"nounderline abstract_t\">Christensen EI, Willnow TE. Essential role of megalin in renal proximal tubule for vitamin homeostasis. J Am Soc Nephrol 1999; 10:2224.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/23\" class=\"nounderline abstract_t\">Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 1982; 79:5557.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/24\" class=\"nounderline abstract_t\">Lundgren S, Carling T, Hj&auml;lm G, et al. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 1997; 45:383.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/25\" class=\"nounderline abstract_t\">Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002; 277:618.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/26\" class=\"nounderline abstract_t\">Cui S, Verroust PJ, Moestrup SK, Christensen EI. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996; 271:F900.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/27\" class=\"nounderline abstract_t\">Nagai J, Tanaka H, Nakanishi N, et al. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001; 281:F337.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/28\" class=\"nounderline abstract_t\">Christensen EI, Birn H, Verroust P, Moestrup SK. Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998; 180:237.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/29\" class=\"nounderline abstract_t\">Bennett WM. Mechanisms of aminoglycoside nephrotoxicity. Clin Exp Pharmacol Physiol 1989; 16:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/30\" class=\"nounderline abstract_t\">Olbricht CJ, Fink M, Gutjahr E. Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity. Kidney Int 1991; 39:639.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/31\" class=\"nounderline abstract_t\">Ford DM, Dahl RH, Lamp CA, Molitoris BA. Apically and basolaterally internalized aminoglycosides colocalize in LLC-PK1 lysosomes and alter cell function. Am J Physiol 1994; 266:C52.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/32\" class=\"nounderline abstract_t\">Takano M, Ohishi Y, Okuda M, et al. Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line. J Pharmacol Exp Ther 1994; 268:669.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/33\" class=\"nounderline abstract_t\">Hori R, Okuda M, Ohishi Y, et al. Surface binding and intracellular uptake of gentamicin in the cultured kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992; 261:1200.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/34\" class=\"nounderline abstract_t\">Spiegel DM, Shanley PF, Molitoris BA. Mild ischemia predisposes the S3 segment to gentamicin toxicity. Kidney Int 1990; 38:459.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/35\" class=\"nounderline abstract_t\">Wedeen RP, Batuman V, Cheeks C, et al. Transport of gentamicin in rat proximal tubule. Lab Invest 1983; 48:212.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/36\" class=\"nounderline abstract_t\">Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 1979; 15:335.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/37\" class=\"nounderline abstract_t\">Servais H, Van Der Smissen P, Thirion G, et al. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol Appl Pharmacol 2005; 206:321.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/38\" class=\"nounderline abstract_t\">Sandoval R, Leiser J, Molitoris BA. Aminoglycoside antibiotics traffic to the Golgi complex in LLC-PK1 cells. J Am Soc Nephrol 1998; 9:167.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/39\" class=\"nounderline abstract_t\">Sandvig K, Ryd M, Garred O, et al. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol 1994; 126:53.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/40\" class=\"nounderline abstract_t\">Lord JM, Roberts LM. Toxin entry: retrograde transport through the secretory pathway. J Cell Biol 1998; 140:733.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/41\" class=\"nounderline abstract_t\">Sandoval RM, Molitoris BA. Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am J Physiol Renal Physiol 2004; 286:F617.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/42\" class=\"nounderline abstract_t\">Sandvig K, Garred O, van Helvoort A, et al. Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells. Mol Biol Cell 1996; 7:1391.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/43\" class=\"nounderline abstract_t\">Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med 2002; 69:289.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/44\" class=\"nounderline abstract_t\">Baciewicz AM, Sokos DR, Cowan RI. Aminoglycoside-associated nephrotoxicity in the elderly. Ann Pharmacother 2003; 37:182.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/45\" class=\"nounderline abstract_t\">Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:786.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/46\" class=\"nounderline abstract_t\">Bacopoulou F, Markantonis SL, Pavlou E, Adamidou M. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care 2003; 18:107.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/47\" class=\"nounderline abstract_t\">Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003; 41:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/48\" class=\"nounderline abstract_t\">Beauchamp D, Laurent G, Maldague P, et al. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid. J Pharmacol Exp Ther 1990; 255:858.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/49\" class=\"nounderline abstract_t\">Kishore BK, Lambricht P, Laurent G, et al. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids. J Pharmacol Exp Ther 1990; 255:875.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/50\" class=\"nounderline abstract_t\">Ramsammy LS, Josepovitz C, Lane BP, Kaloyanides GJ. Polyaspartic acid protects against gentamicin nephrotoxicity in the rat. J Pharmacol Exp Ther 1989; 250:149.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/51\" class=\"nounderline abstract_t\">Williams PD, Hottendorf GH, Bennett DB. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther 1986; 237:919.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/52\" class=\"nounderline abstract_t\">Kishore BK, Ibrahim S, Lambricht P, et al. Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats. J Pharmacol Exp Ther 1992; 262:424.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/53\" class=\"nounderline abstract_t\">Josepovitz C, Pastoriza-Munoz E, Timmerman D, et al. Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations. J Pharmacol Exp Ther 1982; 223:314.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/54\" class=\"nounderline abstract_t\">Kishore BK, K&aacute;llay Z, Lambricht P, et al. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro. J Pharmacol Exp Ther 1990; 255:867.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/55\" class=\"nounderline abstract_t\">Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol 1995; 26:1477.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/56\" class=\"nounderline abstract_t\">Ben Ismail TH, Ali BH, Bashir AA. Influence of iron, deferoxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen Pharmacol 1994; 25:1249.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/57\" class=\"nounderline abstract_t\">Ali BH, Bashir AK. Effect of superoxide dismutase treatment on gentamicin nephrotoxicity in rats. Gen Pharmacol 1996; 27:349.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/58\" class=\"nounderline abstract_t\">Ali BH, Mousa HM. Effect of dimethyl sulfoxide on gentamicin-induced nephrotoxicity in rats. Hum Exp Toxicol 2001; 20:199.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/59\" class=\"nounderline abstract_t\">Sandhya P, Mohandass S, Varalakshmi P. Role of DL alpha-lipoic acid in gentamicin induced nephrotoxicity. Mol Cell Biochem 1995; 145:11.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/60\" class=\"nounderline abstract_t\">Mazzon E, Britti D, De Sarro A, et al. Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2001; 424:75.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/61\" class=\"nounderline abstract_t\">Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54:1299.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/62\" class=\"nounderline abstract_t\">Ozbek E, Turkoz Y, Sahna E, et al. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int 2000; 85:742.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/63\" class=\"nounderline abstract_t\">Sandoval RM, Reilly JP, Running W, et al. A non-nephrotoxic gentamicin congener that retains antimicrobial efficacy. J Am Soc Nephrol 2006; 17:2697.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/64\" class=\"nounderline abstract_t\">Nudelman I, Glikin D, Smolkin B, et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 2010; 18:3735.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/65\" class=\"nounderline abstract_t\">Wang D, Belakhov V, Kandasamy J, et al. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab 2012; 105:116.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/66\" class=\"nounderline abstract_t\">Rowe SM, Sloane P, Tang LP, et al. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med (Berl) 2011; 89:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/67\" class=\"nounderline abstract_t\">Nudelman I, Rebibo-Sabbah A, Cherniavsky M, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009; 52:2836.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/68\" class=\"nounderline abstract_t\">Richardson R, Smart M, Tracey-White D, et al. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders. Exp Eye Res 2017; 155:24.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/69\" class=\"nounderline abstract_t\">Baradaran-Heravi A, Niesser J, Balgi AD, et al. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity. Proc Natl Acad Sci U S A 2017; 114:3479.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/70\" class=\"nounderline abstract_t\">Dobie RA, Black FO, Pezsnecker SC, Stallings VL. Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. Arch Otolaryngol Head Neck Surg 2006; 132:253.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/71\" class=\"nounderline abstract_t\">Black FO, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol 2004; 25:559.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/72\" class=\"nounderline abstract_t\">Basile AS, Huang JM, Xie C, et al. N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss. Nat Med 1996; 2:1338.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/73\" class=\"nounderline abstract_t\">Ernfors P, Duan ML, ElShamy WM, Canlon B. Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Nat Med 1996; 2:463.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/74\" class=\"nounderline abstract_t\">Wu WJ, Sha SH, Schacht J. Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol Neurootol 2002; 7:171.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/75\" class=\"nounderline abstract_t\">Sinswat P, Wu WJ, Sha SH, Schacht J. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int 2000; 58:2525.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/76\" class=\"nounderline abstract_t\">Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4:289.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/77\" class=\"nounderline abstract_t\">Casano RA, Johnson DF, Bykhovskaya Y, et al. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. Am J Otolaryngol 1999; 20:151.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/78\" class=\"nounderline abstract_t\">Hamasaki K, Rando RR. Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Biochemistry 1997; 36:12323.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/79\" class=\"nounderline abstract_t\">Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000; 9:1787.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/80\" class=\"nounderline abstract_t\">Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A--&gt;G mutation in European children. N Engl J Med 2009; 360:640.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/81\" class=\"nounderline abstract_t\">Vandebona H, Mitchell P, Manwaring N, et al. Prevalence of mitochondrial 1555A--&gt;G mutation in adults of European descent. N Engl J Med 2009; 360:642.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/82\" class=\"nounderline abstract_t\">Aran JM. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg 1995; 112:133.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/83\" class=\"nounderline abstract_t\">Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72:359.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/84\" class=\"nounderline abstract_t\">Tokgoz B, Ucar C, Kocyigit I, et al. Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. Nephrol Dial Transplant 2011; 26:4073.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/85\" class=\"nounderline abstract_t\">Tepel M. N-Acetylcysteine in the prevention of ototoxicity. Kidney Int 2007; 72:231.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/86\" class=\"nounderline abstract_t\">Chen Y, Huang WG, Zha DJ, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 2007; 226:178.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/87\" class=\"nounderline abstract_t\">Sha SH, Qiu JH, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006; 354:1856.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/88\" class=\"nounderline abstract_t\">Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007; 72:931.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity/abstract/89\" class=\"nounderline abstract_t\">Huth ME, Han KH, Sotoudeh K, et al. Designer aminoglycosides prevent cochlear hair cell loss and hearing loss. J Clin Invest 2015; 125:583.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7242 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">NEPHROTOXICITY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Renal transport of aminoglycosides</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Proximal tubule cell transport and charge</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">Prevention</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Clinical strategies</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Agents</a></li></ul></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">OTOTOXICITY</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Pathogenesis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Prevention of ototoxicity</a></li></ul></li><li><a href=\"#H481347434\" id=\"outline-link-H481347434\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides\" class=\"medical medical_review\">Dosing and administration of parenteral aminoglycosides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=manifestations-of-and-risk-factors-for-aminoglycoside-nephrotoxicity\" class=\"medical medical_review\">Manifestations of and risk factors for aminoglycoside nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-etiology-and-differential-diagnosis-of-vertigo\" class=\"medical medical_review\">Pathophysiology, etiology, and differential diagnosis of vertigo</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-chronic-kidney-disease-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Chronic kidney disease in adults</a></li></ul></div></div>","javascript":null}